[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"joint-hypermobility\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:joint-hypermobility":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,68,106,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":38,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100646071","phase-1-regenerative-medicine-for-joint-hypermobility-and-instability-100646071",false,"NCT07688096","Regenerative Medicine for Joint Hypermobility and Instability","Regenerative Medicine for Joint Hypermobility and Instability: A Prospective, Open-Label, Single-Arm, Step-Care Clinical Study","Inclusion Criteria:\n\n* Adults age 18 years or older, any gender.\n* Symptomatic joint hypermobility or instability attributable to one of the following:\n\n  1. hEDS diagnosed using the 2017 International Classification of the Ehlers-Danlos Syndromes diagnostic criteria;\n  2. HSD classified using the 2017 framework (generalized, peripheral, localized, or historical HSD) with Beighton scoring; or\n  3. post-traumatic joint instability with ligamentous injury documented by examination and\u002For imaging.\n* Objective evidence of instability or clinically relevant hypermobility at one or more target joints, defined as at least one of:\n\n  1. a positive joint-specific instability provocation test on standardized physical examination;\n  2. generalized hypermobility (Beighton score ≥ 5\u002F9 for adults) or documented joint-specific hypermobility at the target joint; or\n  3. imaging evidence of ligamentous laxity or injury at the target joint (dynamic ultrasound, stress radiograph, or MRI).\n* Pain attributable to the target joint for at least 3 months.\n* Baseline pain score of 4 or greater on a 0-10 numeric rating scale.\n* Failure of conservative treatment, including at least 6 weeks of physical therapy directed at the affected joint(s).\n* Not currently using NSAIDs and willing to avoid NSAIDs during the active treatment period, when clinically appropriate.\n* Able to provide informed consent and to comply with study procedures and follow-up.\n\nAdditional eligibility for the Hyaluronic Acid (HA) alternative pathway - a participant may enter the HA pathway if ALL of the following apply, in addition to the inclusion criteria above:\n\n* Has completed at least one regenerative medicine phase (dextrose, PRP, or doxycycline) and either\n\n  1. was classified as an inadequate responder at the phase decision point (GPI \\\u003C 40%) and declined further regenerative rotation,\n  2. completed all available regenerative phases without adequate response, or\n  3. experienced an adverse reaction during a regenerative phase that, in the investigator's judgment, contraindicates further regenerative treatment.\n* A minimum waiting period of 4 weeks has elapsed since the last regenerative medicine treatment attempted, to allow resolution of post-injection effects before HA administration.\n* The target joint(s) have clinical or imaging features amenable to HA viscosupplementation (e.g., articular\u002Fosteoarthritic pain component identifiable on examination or imaging).\n* No contraindication to HA (see Exclusion Criteria).\n\nExclusion Criteria:\n\n* Impaired decision-making capacity that precludes valid informed consent.\n* Active local or systemic infection.\n* Known allergy or contraindication to study injections, local anesthetics, iodinated contrast (if fluoroscopy is planned), or required procedural materials.\n* Known hypersensitivity or intolerance to tetracycline-class antibiotics, including doxycycline (relevant to the doxycycline treatment phase).\n* Mast cell activation syndrome (MCAS) or other mast cell disorder that, in the investigator's judgment, elevates the risk of injection-related hypersensitivity or systemic reactions.\n* Active autoimmune or systemic inflammatory connective-tissue disease that, in the investigator's judgment, may confound the response to regenerative treatment or increase procedural risk.\n* Known hypersensitivity to sodium hyaluronate or to the specific HA product to be used (Visco-3); active skin disease or infection over the planned injection site; venous or lymphatic stasis in the limb of the planned injection.\n* Active malignancy or anticancer treatment within the prior 12 months; a prior malignancy in documented remission may be enrolled at the investigator's discretion with documented rationale.\n* Uncontrolled diabetes mellitus, defined as HbA1c ≥ 8.5% on the most recent value within the prior 3 months; the investigator may also exclude for other objectively documented diabetes-related procedural or healing risk.\n* Prior joint replacement at the target joint.\n* Planned surgery during study participation.\n* Corticosteroid injection to the target joint(s) within the prior 6 weeks.\n* Concurrent enrollment in another interventional study for the same pain condition.\n* Active litigation or disability claim related to the target condition (to limit secondary-gain confounding of self-reported outcomes).\n* Pregnancy, or unwillingness to undergo pregnancy testing when fluoroscopy is planned (persons of childbearing potential).\n* Inability to comply with study procedures or follow-up.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This clinical trial is designed to evaluate whether a stepwise injection-based treatment approach can reduce pain and improve function in adults with joint hypermobility, connective tissue laxity, and joint instability.\n\nJoint hypermobility occurs when joints move beyond their normal range, often because of looser connective tissue. For some patients, this can contribute to chronic pain, recurrent instability, reduced function, and disability. This study focuses on adults with hypermobile Ehlers-Danlos syndrome (hEDS), hypermobility spectrum disorder (HSD), or joint instability after injury who have already completed physical therapy without adequate relief.\n\nThe main question this study aims to answer is whether the first treatment step, dextrose prolotherapy, can reduce pain by 40% or more two weeks after the second injection.\n\nParticipants will receive treatment in a step-by-step sequence, based on their response:\n\nStep 1: Dextrose prolotherapy A dextrose-based injection used to stimulate a healing response in ligament, tendon, or joint-supporting tissue.\n\nStep 2: Platelet-rich plasma (PRP) An injection prepared from the participant's own blood, designed to support tissue repair and recovery.\n\nStep 3: Doxycycline injections A low-dose injectable treatment used in this study to help protect joint-supporting tissue. It is not being used to treat infection.\n\nAlternative option: Hyaluronic acid injections An injection into the joint that may be offered if the earlier treatment steps do not provide enough improvement.\n\nEach treatment step begins with two injections, given approximately two weeks apart. If a participant improves by 40% or more, they may continue with that treatment pathway. If they do not improve enough, they may be offered the next step in the study.\n\nParticipants will be followed for up to 12 months, with study visits used to monitor pain, function, treatment response, and safety.",[27,28,29,30,31,32,33,34,35,36,37],"Ehlers-Danlos Syndrome Hypermobility Type (hEDS)","Ehlers-Danlos Syndrome (EDS)","Joint Hypermobility","Joint Instability","Hypermobility Spectrum Disorder","Chronic Pain Syndrome","Musculoskeletal Pain","Sprain","Subluxation","Dislocation","Craniocervical Disfunction",[39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,35,54,37,55],"prolotherapy","dextrose prolotherapy","platelet-rich plasma","PRP","doxycycline","regenerative medicine","joint hypermobility","hEDS","hypermobile Ehlers-Danlos syndrome","viscosupplementation","hyaluronic acid","step-care","ligament instability","MMP inhibition","dislocation","CCI","Craniocervical instability","NOT_YET_RECRUITING","2026-07-08",{"date":59,"type":60},"2026-07-10","ACTUAL",{"date":62,"type":20},"2026-07-15",{"date":64,"type":20},"2028-12-31",{"name":66,"class":67},"Manhattan Pain Medicine, PLLC","OTHER",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":86,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100615546","investigation-of-medial-longitudinal-arch-and-foot-function-in-patients-with-lipedema-100615546","NCT07294014","Investigation of Medial Longitudinal Arch and Foot Function in Patients With Lipedema","Investigation of Medial Longitudinal Arch and Foot Function in Patients With Lipedema: A Cross-Sectional Study","General Inclusion Criteria (Apply to All Participants)\n\n* Female participants\n* Age 18 years or older\n* Able to read and write (literacy requirement)\n* Availability of bilateral lateral foot radiographs obtained within the past 1 year in the hospital PACS system\n* Willing and able to provide written and verbal informed consent\n\nAdditional eligibility criteria for Lipedema Group\n\n\\- Clinical diagnosis of lipedema according to Halk and Damstra criteria.\n\nAdditional eligibility criteria for Control group:\n\n* Female patients presenting with nonspecific foot pain\n* Similar age and BMI range as the lipedema group\n* No clinical diagnosis or suspicion of lipedema\n\nExclusion Criteria (Apply to all participants)\n\n* Pregnancy\n* Illiteracy\n* Inability or unwillingness to provide written and verbal informed consent\n* History of lower extremity fracture, trauma, or orthopedic surgery\n* Diagnosis of diabetes mellitus\n* Known rheumatologic disease\n* Known polyneuropathy or peripheral nerve injury affecting the lower extremities",true,"FEMALE","65 Years",{"count":79,"type":20},32,"OBSERVATIONAL","Lipedema is a chronic adipose tissue disorder that commonly leads to joint laxity, hypermobility, and functional limitations, yet its impact on foot morphology has not been systematically examined. This case-control study aims to investigate whether patients with lipedema exhibit a higher prevalence of generalized joint hypermobility and foot structural abnormalities-specifically pes planus-compared with age- and BMI-matched controls. Using radiographic measurements (Meary angle and calcaneal inclination angle), clinical hypermobility assessment, and validated functional scales, the study seeks to determine the relationship between lipedema, hypermobility, and foot function.",[83,84,85,29],"Lipedema","Hypermobility Syndrome (Disorder)","Pes Planus",[87,88,89,90,91,92,93,94],"lipedema","mypermobility","foot function","pes planus","joint hyper mobility","foot morphology","Meary angle","calcaneal inclination angle","RECRUITING","2025-12-31",{"date":98,"type":60},"2026-01-02",{"date":100,"type":20},"2026-01-01",{"date":102,"type":20},"2026-04-01",{"name":104,"class":67},"Marmara University",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":105},"100506194","functional-instability-in-patients-suffering-from-collagen-disease-and-joint-hypermobility-100506194","NCT05871216","Functional Instability in Patients Suffering From Collagen Disease and Joint Hypermobility","Evaluation of Functional Instability Using the \"Delos Proprioceptive System\" in Patients Suffering From Collagen Disease and Joint Hypermobility","VIPIA","Inclusion Criteria:\n\n* Patients with moderate (Beighton-Horan Joint Mobility Index score from 3 to 4) or severe (Beighton-Horan Joint Mobility Index score from 5 to 9) joints hyperlaxity at the clinical evaluation\n\nExclusion Criteria:\n\n* Obesity (BMI \\> 25) and weight \\> 90 kg\n* Practice of competitive sport\n* Orthopedic (complex surgery of the spine and lower limbs), neurological (spasticity, stroke), and oncological comorbidities\n* Orthostatic \u002F walking inability\n* Absence of joints hyperlaxity at the clinical evaluation (Beighton-Horan Joint Mobility Index score from 0 to 2)","60 Years",{"count":116,"type":20},30,"A joint is considered \"hypermobile\" when it has a greater range of motion than normal for a given age, ethnicity or gender. Many people have asymptomatic hyperlaxity in multiple joints, a condition called Generalized Joint Hypermobility (GJH).\n\nConversely, hyperlaxity can be symptomatic, a condition that has been defined \"Joint Hypermobility Syndrome\" - JHS.\n\nDiagnosis of JHS is commonly performed by applying the revised Brighton criteria. Based on these criteria, an individual is diagnosed with JHS with a Beighton score \\>\u002F= 4\u002F9, and arthralgia for 3 or more months in 4 or more joints (major criteria).\n\nThe dynamic body balance test (i.e. the stability test with multiple single-leg jumps) can provide information regarding the effectiveness of the feedforward and feedback mechanisms in correcting the postural deviations necessary to achieve successful performance during daily and sporting activities. Such assessment may also be useful to demonstrate deficiencies in balance, especially in young patients with increased physical activity.\n\nThe aim of this study is to examine the postural balance of individuals with JHS by performing stability tests in monopodalic and bipodalic stance with the \"Delos Postural Proprioceptive System\"",[119,120,121,29,122],"Hypermobility Syndrome","Danlos Disease, Ehlers","Collagen Diseases","Laxity of Ligament","2025-07-18",{"date":125,"type":60},"2025-07-20",{"date":127,"type":60},"2020-10-01",{"date":129,"type":20},"2026-03-30",{"name":131,"class":67},"Istituto Ortopedico Rizzoli",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":139,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":140,"conditions":141,"keywords":144,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":156,"locationsCount":105},"100454389","the-clinical-outcomes-of-the-modified-brostrm-vs-anatomic-reconstruction-operation-in-clai-and-gjl-100454389","NCT05196906","The Clinical Outcomes of the Modified Broström vs Anatomic Reconstruction Operation in CLAI and GJL","The Clinical Outcomes Comparing the Modified Broström vs Anatomic Reconstruction Operation in Chronic Lateral Ankle Instability and Generalized Joint Laxity","Inclusion Criteria:\n\nClinical diagnosis of lateral ankle pain and instability Beighton score ≥4 Age with 18 to 60 years\n\nExclusion Criteria:\n\nPatients with an acute or subacute ankle injury (within 3 months) Injury of the deltoid ligament Alignment of lower extremity greater than 5 degrees Fractures of the lower extremity Stage III or IV osteoarthritis Patients who refused to participate in the study",{"count":19,"type":20},"Investigators designed this prospective cohort study to compare the clinical outcomes of modified Broström operation and anatomical reconstruction for the treatment of CLAI and GJL.",[142,143,29],"Ankle Sprains","Instability, Joint",[145,146,147,148,149],"chronic lateral ankle instability","generalized joint laxity","re-injury","modified Brostrom operation","anatomic reconstruction","2025-04-08",{"date":152,"type":60},"2025-04-11",{"date":154,"type":60},"2020-01-01",{"date":96,"type":20},{"name":157,"class":67},"Peking University Third Hospital"]